June 23 (Reuters) - Palvella Therapeutics Inc PVLA.O:
PALVELLA THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 3 SELVA TRIAL OF QTORIN™ RAPAMYCIN FOR MICROCYSTIC LYMPHATIC MALFORMATIONS, EXCEEDING ENROLLMENT TARGET BY OVER 25%
PALVELLA THERAPEUTICS INC - TOP-LINE DATA EXPECTED IN Q1 2026
Source text: ID:nGNX3QLmt2
Further company coverage: PVLA.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.